The development of gut hormone dual- and triagonists holds promise for treating obesity and T2DM with a level of effectiveness comparable to bariatric surgery
Advertisement Sign up for our Health Essentials emails for expert guidance on nutrition, fitness, sleep, skin care and more
The impact of improved glycaemic control with GLP-1 receptor agonists on diabetic retinopathy
(See Figure 2 for a timeline of key activities associated with the GLP-1 coverage demonstrations.) Medicare coverage of GLP-1s for obesity begins in July 2026 through the Medicare GLP-1 Bridge and will be extended through the end of 2027 CMS will provide Part D beneficiaries with coverage of select GLP-1s for obesity from July 1, 2026 to December 31, 2027 (originally December 31, 2026) through the Medicare GLP-1 Bridge, which is a short-term demonstration established using Section 402 demonstration authority
Adjusting expectations to match real-world patterns reduces unnecessary anxiety
21, 2025 Indiana HB1138 and Indiana HB1202 and Indiana HB1552 BillTrack50
